Hormonal
High body mass index (BMI) and obesity are strong, independent risk factors for the development and progression of chronic kidney disease (CKD), end-stage renal disease (ESRD), and obesity-related glomerulopathy (ORG).
Maintaining a healthy body weight is one of the most effective ways to prevent chronic kidney disease. High BMI increases pressure inside the kidney's filtering units (glomeruli) and triggers inflammatory hormones from fat tissue that directly damage kidney structure over time. Even if you do not have diabetes or high blood pressure, excess weight—especially around the waist—increases your risk of kidney failure. Weight management through diet and exercise is a primary preventive strategy for kidney health.
A high body mass index (BMI) is one of the strongest risk factors for new-onset Chronic kidney disease... The increase in intraglomerular pressure can damage the kidneys and raise the risk of developing Chronic kidney disease in the long-term. The incidence of obesity-related glomerulopathy has increased ten-fold in recent years.
Why this rating
Based on numerous population-based studies, meta-analyses, and consistent observational data, though exact mechanisms are complex.
Source
Obesity and kidney disease: hidden consequences of the epidemic
Csaba P. Kövesdy et al. · Revista médica de Chile · 2017
DOI 10.4067/s0034-98872017000300001
More from this paper
- Obesity is a significant risk factor for kidney cancer, with a 5 kg/m2 higher BMI associated with a 25% higher risk of kidney cancers, and 10-26% of all kidney cancers attributable to excess weight.Strong
- Obesity increases the risk of nephrolithiasis (kidney stones) through mechanisms including lower urine pH, increased urinary oxalate, uric acid, and sodium excretion, and insulin resistance-induced acidic urine.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →